ENHO and Marchiafava-Bignami disease: However, to our knowledge, no study demonstrates the comparison and correlation of traditional cardiovascular risk biomarkers (lipids), non-traditional cardiovascular risk biomarkers such as CKD-MBD parameters, and novel biomarkers (adropin and afamin) in various stages of CKD.